Physician profile
David E Montgomery
NPI 1407027014
$9,397.57
in general payments reported to CMS, 2019-2025
24 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $6,786 · 2021: $737 · 2022: $250 · 2023: $318 · 2024: $488 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $6,971.89 | 2019-2021 | |
| Amgen INC. | $431.82 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $388.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $320.10 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $265.83 | 2019-2022 | |
| Esperion Therapeutics, INC. | $205.58 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $89.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.71 | 2021-2022 | |
| Vital Connect, INC | $78.95 | 2024-2025 | Vitalpatch Rtm |
| Philips North America LLC | $73.77 | 2020-2024 | (5050) Extended Holter |
| Edwards Lifesciences Corporation | $69.15 | 2019-2021 | |
| Pfizer INC. | $61.14 | 2022-2023 | |
| Abbott Laboratories | $46.17 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $41.73 | 2024-2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $36.38 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $36.30 | 2023-2024 | Edarbyclor, Edarbyclor |
| Kowa Pharmaceuticals America, INC. | $33.36 | 2019-2020 | |
| Heartflow, INC. | $31.39 | 2022-2025 | |
| Medtronic, INC. | $26.45 | 2025 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $25.94 | 2019 | |
| Braemar Manufacturing, LLC | $23.15 | 2019 | |
| Orexo US, INC. | $19.76 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.23 | 2024 | Evkeeza, Praluent |
| Lantheus Medical Imaging, INC. | $18.01 | 2023 | Definity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.